A 48-year-old man with erythematous, maculopapular rash localized to his extremities and lumbar region that he had been receiving oral pregabalin 300 mg per day for 2 months to treat his neuropathy was applied. The Naranjo probability scale indicates a probable relationship between the development of rash and use of pregabalin by our patient. Pregabalin was discontinued and antihistaminic treatment, oral methyprednisolone and topical steroid cream were given to treat the rash. The rash almost completely resolved one week after pregabalin was discontinued. Pregabalin-induced rash was rarely reported in Phase 3 clinical trials, and there is currently only one available report on the development of a rash coinciding with the use of pregabalin. No clear mechanisms reported for rash associated with pregabalin. It is usually recommended to start pregabalin with low doses and slow increases might prevent the incidence of side effects.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.